对第一次复发的高度血清卵巢癌进行二线化疗的比较:一项回顾性研究
Jeongyun Kim1, Se Ik Kim1, Dong Hoon Suh1,2
1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Journal of clinical medicine
|October 16, 2025
概括
对于复发的高度血清性卵巢癌 (HGSOC) 的二线化疗表明,对敏感的患者,taxane + platinum疗法是有效的. 维护疗法和贝瓦齐祖马布的使用可能会改善抗性疾病的结果.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 临床研究 临床研究
背景情况:
- 复发的高度血清卵巢癌 (HGSOC) 需要有效的二线化疗策略.
- 敏感性是影响复发性卵巢癌治疗结果的关键因素.
研究的目的:
- 为了比较不同二线化疗方案在复发性HGSOC中的瘤结果.
- 评估敏感性对治疗疗效和存活率的影响.
主要方法:
- 在2003年6月至2020年12月期间接受治疗的468名HGSOC患者的回顾性评估.
- 根据无时间间隔 (截止时间为6个月和12个月) 将患者分类为对敏感,部分敏感和耐药的组.
- 使用多变量Cox分析进行无进展生存 (PFS),客观反应率和疾病控制率的比较.
主要成果:
- 与部分敏感 (10.5个月) 和耐药 (5.2个月) 组相比,对敏感的患者的PFS中位数显著更长 (14.8个月).
- 在对敏感的患者中,taxane + platinum ± bevacizumab疗法是最常见的,并且在敏感的患者中表现优于化脂质体 doxorubicin + carboplatin.
- 用贝瓦齐祖马布或多 (ADP-ribose) 聚合酶抑制剂的二线维护改善了这两个敏感组的PFS;贝瓦齐祖马布的使用和之前的细胞减小手术与白金耐药性疾病的更好的结果有关.
结论:
- 塔克森+白金疗法在白金敏感性复发性HGSOC中优于PLD+碳白金.
- 维护疗法和贝瓦齐祖马布在HGSOC的二线治疗中是有益的.
- 治疗选择和手术方法,包括贝瓦西祖马布和细胞减小手术,对于优化抗性HGSOC的结果至关重要.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Comparing the Survival Analysis of Two or More Groups
551
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
551


